과민성 방광 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Overactive Bladder Treatment Market size is expected to reach USD 6.57 Billion in 2034 from USD 4.29 Billion (2025) growing at a CAGR of 4.86% during 2026-2034.

The global overactive bladder (OAB) treatment market is growing steadily due to the rising prevalence of urinary disorders, particularly among the aging population. Increasing awareness about bladder health and improved diagnostic methods are supporting early treatment. Pharmaceutical therapies, neuromodulation devices, and minimally invasive procedures are widely adopted to manage symptoms effectively.

Key growth drivers include advancements in drug formulations with improved safety profiles and reduced side effects. Expanding healthcare coverage and growing patient willingness to seek treatment are also contributing to market expansion. In addition, ongoing research into novel therapeutic targets is strengthening the product pipeline for OAB management.

Future prospects appear promising with the development of combination therapies and innovative medical devices. Increasing acceptance of minimally invasive treatments and home-based management options may further enhance patient compliance. Emerging markets are expected to witness higher growth due to improving healthcare infrastructure and rising awareness levels.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Condition Type

• Neurogenic Bladder
• Idiopathic Bladder

By Treatment Type

• Drug Therapy
• Botox Treatment
• Neuromodulation
• Other Treatment Types

COMPANIES PROFILED

• AbbVie Inc, Astellas Pharma Inc, Axonics Inc, BlueWind Medical, Cipla Ltd, Endo International plc, Laborie, Lupin Ltd, Medtronic plc, Merck Co, Pfizer Inc, Sumitomo Pharma America Inc Urovant Sciences, Teva Pharmaceutical Industries Ltd, Viatris Inc, Zydus Lifesciences Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET: BY CONDITION TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Condition Type
• 4.2. Neurogenic Bladder Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Idiopathic Bladder Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Treatment Type
• 5.2. Drug Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Botox Treatment Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Neuromodulation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Other Treatment Types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Condition Type
  • 6.2.2 By Treatment Type
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Condition Type
  • 6.3.2 By Treatment Type
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Condition Type
  • 6.4.2 By Treatment Type
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Condition Type
  • 6.5.2 By Treatment Type
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Condition Type
  • 6.6.2 By Treatment Type
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL OVERACTIVE BLADDER TREATMENT INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 AbbVie Inc
  • 8.2.2 Astellas Pharma Inc
  • 8.2.3 Axonics Inc
  • 8.2.4 BlueWind Medical
  • 8.2.5 Cipla Ltd
  • 8.2.6 Endo International Plc
  • 8.2.7 Laborie
  • 8.2.8 Lupin Ltd
  • 8.2.9 Medtronic Plc
  • 8.2.10 Merck & Co
  • 8.2.11 Pfizer Inc
  • 8.2.12 Sumitomo Pharma America Inc. (Urovant Sciences)
  • 8.2.13 Teva Pharmaceutical Industries Ltd
  • 8.2.14 Viatris Inc
  • 8.2.15 Zydus Lifesciences Ltd